A Phase 1, Open-label Study to Evaluate the Pharmacokinetics of Thalidomide Following Multiple Oral Dosing in Subjects With Multiple Myeloma.
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 02 May 2016 Status changed from recruiting to completed.
- 01 Mar 2016 Planned End Date changed from 1 Jan 2016 to 1 May 2016 as reported by ClinicalTrials.gov record.
- 01 Mar 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.